| Name | Title | Contact Details |
|---|
About Liberty Federal Credit Union Liberty Federal Credit Union is a member-owned financial institution focused on returning value through innovative products and services. Liberty has been recognized on a state level by Forbes as one of Indianas best financial institutions. In recent years, the credit union has also received acclaim on a national level, including being named the nations Best Credit Union for Checking by Investopedia in 2021 and appearing on Newsweeks list of Americas Best Banks in 2022. Among Liberty FCUs most innovative products is its Vertical Checking. This free checking account offers a high interest rate of 3.30% APY on balances up to $20,000, plus reimbursement for usage fees paid when using any ATM worldwide up to $15 per month. However, Liberty Federal Credit Union similarly excels in providing value through better loan options for borrowers. For instance, the credit union offers an uncommonly wide variety of mortgage options to ensure the best fit for its members. According to the American Credit Union Mortgage Association, Liberty FCU was the Midwests top credit union in 2021 total first mortgage originations. Nationally, we ranked eleventh. Headquartered in Evansville, Indiana, Liberty FCU offers a wide footprint of branch locations throughout southern Indiana, western Kentucky, and the Greater Nashville area in Tennessee. However, the credit union currently serves more than 270,000 members across all fifty states and at least eight countries.
Tanenholz & Associates is a Washington, D.C. based law firm specializing in all aspects of discovery, from initial consultation to the end-to-end management of large-scale document reviews. With years of big-firm litigation experience, Tanenholz & Associates understands that well-planned and high quality document review can both minimize litigation costs and maximize litigation efficiencies. Providing flexible teams of skilled contract attorneys led by experienced senior associates, Tanenholz & Associates is uniquely equipped to manage your discovery needs.
BHS Corrugated – leading provider of solutions for the corrugated industry BHS Corrugated is the leading provider of solutions for the corrugated industry with 3,000 employees at headquarters in Weiherhammer, Germany as well as in more than 20 countries. As Lifecycle Partner, BHS Corrugated is consistently strong across the entire product and service range: from development and production, to installation and maintenance, to a variety of innovative Lifecycle Service solutions in the areas of corrugating rolls, individual machines, complete corrugators, industry 4.0, logistics and soon to come digital print in- and outside the corrugator. Significant aspects of digitalization, primarily regarding the optimization of process parameters and increasing degrees of automation and production efficiency, have been central issues of BHS Corrugated for many years. To meet the requirements of its customers as precisely as possible and to be always state-of-the-art, BHS Corrugated reinvests close to 5 percent of its turnover in research and development. In addition to its core business, BHS Corrugated supports different social projects, for example the familys own foundation "Angels for Children" or the "Lars und Christian Engel Stiftung (LUCE Trust)", which supports technological and economic development in the region. Contact: BHS Corrugated Maschinen- und Anlagenbau GmbH Paul-Engel-Str. 1 92729 Weiherhammer info@bhs-world.com Tel. +49 9605 919 0 bhs-world.com
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.